Clin2
NCT06649656Worth exploringNot yet recruiting

Testing TQB2252 for advanced solid tumors or lymphoma

Advanced Cancers

Part of Cancer clinical trials.

This phase 1 trial tests an experimental drug called TQB2252 for people with advanced cancers that have not responded to standard treatments. The drug blocks a protein called LAG3 to help the immune system attack cancer cells.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
100 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have advanced cancer (solid tumor or lymphoma) that has gotten worse after standard treatments, or no standard treatments exist.
  • You are well enough to be up and active (ECOG 0 or 1).
  • You have at least one tumor that can be measured on a scan.
  • You have not had a similar anti-LAG3 drug before.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07260708Recruiting· Phase 1
Testing TQB2922 injection for advanced lung cancer

This trial tests a new injection called TQB2922 for people with advanced non-squamous non-small cell lung cancer who have already tried standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.

Guangzhou, Guangdong
NCT06413953Recruiting· Phase 1
Testing TQB3107 for advanced solid tumors

This trial is testing a new oral medication called TQB3107 for people with advanced solid tumors (cancer that has spread or cannot be removed). The study aims to see if the drug is safe and how well it works.

Guangzhou, Guangdong
NCT07338838Recruiting· Phase 1
Testing TQB3142 in advanced tumors

This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.

Guangzhou, Guangdong
NCT06948539Not yet recruiting· Phase 1
Testing TQB2101 for advanced solid tumors

This trial tests an experimental drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to understand how the body handles the drug and what side effects may occur. It may be an option if your tumor has a specific marker called ROR1.

Guanzhou, Guangdong
NCT06662760Recruiting· Phase 1
TQB3002 for advanced cancers when standard treatments fail

This trial tests an experimental oral drug called TQB3002 for people with advanced solid tumors who have run out of standard options. Researchers are learning the best dose and how safe it is, with the hope of controlling or shrinking the cancer.

Guangzhou, Guangdong
NCT07697443Not yet recruiting· Phase 1/Phase 2
Study of TQB3126 for breast cancer that has progressed

This study tests a new drug called TQB3126 for people with breast cancer that has worsened after previous treatments. The goal is to see if the drug is safe, how your body processes it, and if it can help shrink or slow the cancer.

Guangzhou, Guangdong

Hear when a new Advanced Cancers trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.